RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
== Illicit use == Dermorphin has been illegally used in horse racing as a performance-enhancing drug. Due to dermorphin's painkilling activity, horses treated with dermorphin may run harder than they would otherwise.
In Weeds episode "Lude Awakening" the character Celia Hodes, portrayed by actress Elizabeth Perkins, states, "I hold in my hand the last Quaalude on earth. See you around, girls." Season 18 of Law & Order: Special Victims Unit addresses Quaalude administration as a date rape drug in episode 9, "Decline and Fall", which aired January 18, 2017. In the first season of True Detective, Rust Cohle's use of Quaaludes is briefly mentioned in several episodes. It is also used by Patrick Melrose in Edward St Aubyn's 1992 novel Bad News. In the 2024 film Maria, Maria Callas, played by Angelina Jolie, stuffs Mandrax into the pockets of her coats and bags so that she'll be able to escape detection by her butler/guardian Ferruccio (Pierfrancesco Favino). The 2000 novel House of Leaves by Mark Z. Danielewski features the supporting character named Lude, referencing Quaaludes. In the 2026 song, Burning Bridges by rapper Drake, he references the substance with the lyric "I'm off a Quay, it make my body tingle”.
Dominion Voting Systems announces that they have sued Fox Corporation and Fox Broadcasting Company, the parent company of Fox News, for defamation and for failing to preserve documents relating to the role Rupert Murdoch played in spreading false claims about Dominion. November 9 – The South Dakota Legislature votes to consider the impeachment of Attorney General Jason Ravnsborg. November 11 – Vice President Harris travels to Paris to deliver a speech at the Paris Peace Forum. November 12 – United States Attorney General Merrick Garland announces that former White House Chief Strategist Steve Bannon has been charged by the Department of Justice for refusing to testify to the January 6 select committee investigating the Capitol riot and refusing to provide documents requested by the committee. Bannon turned himself in to the FBI three days later. November 13 – While speaking before a "ReAwaken America" audience in November 2021, Former Trump National Security Advisor Michael Flynn said, "If we are going to have one nation under God, which we must, we have to have one religion. One nation under God, and one religion under God." causing some outrage. November 15 Radio host and conspiracy theorist Alex Jones is found liable for damages in lawsuits brought by parents of children killed in the Sandy Hook elementary school shooting, over Jones's false claim the massacre was a hoax. President Biden signs the Infrastructure Investment and Jobs Act into law. November 16 – Maryland reports their first case of monkeypox in a resident who traveled from Nigeria. November 17 – The U.S.
Sources: en.wikipedia.org
== Chemistry == LGD-4033 is a nonsteroidal SARM with a pyrrolidinyl-benzonitrile core structure and is also referred to as a quinoline or quinolinone SARM. LG121071 (LGD-121071), a tricyclic quinoline, was the predecessor compound of LGD-4033. The chemical structure of LGD-4033 had not been disclosed as late as 2013. LGD-4033 has sometimes been confused with other structurally related Ligand Pharmaceuticals SARMs including LGD-2226, LGD-2941, and LGD-3303, but is a different compound from these agents. LGD-4033 is a small-molecule (molecular weight = 338.3 g/mol) and highly lipophilic (predicted log P = 3.6–3.7) compound.
=== Legal status === On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camcevi, intended for the treatment of the cancer of the prostate in adult men when the cancer is "hormone-dependent", which means that it responds to treatments that reduce the levels of the hormone testosterone. The applicant for this medicinal product is Accord Healthcare S.L.U. Leuprorelin was approved for medical use in the European Union in May 2022.
In August 1967, brothers Michael and Peter Giles, drummer and singer/bassist respectively, and professional musicians in working bands since their mid-teens in Dorset, England, advertised for a "singing organist" to join a new group they were forming. Fellow Dorset musician Robert Fripp – a guitarist who neither sang or played organ – responded, and Giles, Giles and Fripp was born. The trio signed to Deram Records and recorded one album, The Cheerful Insanity of Giles, Giles and Fripp, released in 1968. They hovered on the edge of success, but were never able to make a commercial breakthrough. Attempting to expand their sound, the three recruited Ian McDonald on keyboards and woodwinds. McDonald brought along two other participants: his then-girlfriend, former Fairport Convention singer Judy Dyble, whose brief tenure with the group ended when the two split, and lyricist, roadie, and art strategist Peter Sinfield, with whom he had been writing songs – a partnership initiated when McDonald had said to Sinfield (regarding his band Creation), "Peter, I have to tell you that your band is hopeless, but you write some great words. Would you like to get together on a couple of songs?" Fripp, meanwhile, saw Clouds at the Marquee Club in London, which spurred him to incorporate classical-inspired melodies into his writing and utilise improvisation to find new ideas. No longer interested in Peter Giles's more whimsical pop songs, Fripp recommended that his old friend, fellow guitarist and singer Greg Lake, could join to replace either Peter or Fripp himself.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.